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Background: The current treatments for human African trypanosomiasis (HAT),
Chagas disease and leishmaniasis (collectively referred to as the kinetoplastid
diseases) are far from ideal but, for some, there has been significant recent
progress. For HAT the only advances in treatment over the past two decades
have been the introduction of an eflornithine/nifurtimox co-administration
and a shorter regime of the old standard melarsoprol.
Sources of data: PubMed.
Areas of Agreement: There is a need for new safe, oral drugs for cost-effective
treatment of patients and use in control programmes for all the trypanosomatid
diseases.
Areas of controversy: Cutaneous leishmaniasis is not on the agenda and
treatments are lagging behind.
Growing points: There are three compounds in development for the treatment
of the CNS stage of HAT: fexinidazole, currently due to entry into phase II
clinical studies, a benzoxaborole (SCYX-7158) in phase I trials and a diamidine
derivative (CPD-0802), in advanced pre-clinical development. For Chagas disease,
two anti-fungal triazoles are now in clinical trial. In addition, clinical studies
with benznidazole, a drug previously recommended only for acute stage
treatment, are close to completion to determine the effectiveness in the
treatment of early chronic and indeterminate Chagas disease. For visceral
leishmaniasis new formulations, therapeutic switching, in particular AmBisome,
and the potential for combinations of established drugs have significantly
improved the opportunities for the treatment in the Indian subcontinent, but
not in East Africa.
Areas timely for developing research: Improved diagnostic tools are needed to
support treatment, for test of cure in clinical trials and for monitoring/
surveillance of populations in control programmes.
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Introduction
Leishmaniasis, human African trypanosomiasis (HAT) and Chagas
disease are caused by taxonomically related kinetoplastid protozoan
parasites that have similar structural and biochemical features. These
include a single mitochondrion with a discrete structured DNA body:
the kinetoplast, specific organelles for glycolysis; the glycosomes, a
sub-pellicular microtubular corset and a unique thiol metabolism.
Recent analysis of the genome sequences has identified both similar
and different metabolic pathways, a new understanding about the
pathogenesis of disease, and has led to further description of biochem-
ical/molecular drug targets.1
These kinetoplastid diseases, also classified as ‘neglected diseases’,
are diseases of poverty that have received limited funding for discovery,
development and delivery of new tools. The drugs that are currently
used for the treatment of the leishmaniases, Chagas disease and HAT
(Table 1) suffer the limitations of toxicity, variable efficacy, require-
ments for parenteral administration and/or length of treatment regi-
mens. For HAT, Chagas and cutaneous leishmaniasis (CL), there are
few drugs or treatments in clinical development, although a pipeline is
emerging. In contrast, for visceral leishmaniasis (VL) there has been
significant progress in the Indian sub-continent with liposomal ampho-
tericin B (AmBisome), miltefosine and paromomycin all proving effect-
ive and registered over the past decade. Importantly, single-dose
liposomal amphotericin B and the co-administration of combinations
from the above three listed drugs show potential for both treatment
and control of VL. Considerable advances in the identification, valid-
ation and characterization of drug targets has accompanied the comple-
tion of the genomes for Trypanosoma cruzi, Trypanosoma brucei and
Leishmania major2 and new tools such as RNAi (in T. brucei and
L. braziliensis) and gene knockout3 have been developed to help
validate potential targets. New and established pharmacophores, based
upon synthetic and natural product chemistry, are being identified
through improved screening technologies to identify hits from libraries
provided by the pharmaceutical industry and elsewhere.4 This is only
one early part of the long and complex process of drug development.
Attention is still required to improve predictive models of infection and
pharmacokinetic studies to evaluate leads and appropriate diagnostic
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Table 1 Drugs in use and on clinical trial.
Drug Comments
VL
First-line drugs Pentavalent antimonials: sodium
stibogluconate (pentostam, generic
SSG)
Parenteral administration; reported
toxicities; resistance in Bihar, India
Meglumine antimoniate
(Glucantime)
Amphotericin B (Fungizone) Slow i.v. infusion; known toxicities,
used in India where there is
resistance to antimonials
Liposomal amphotericin B
(AmBisome)
Further clinical studies on
single-dose infusion in India
Miltefosine First oral drug; concerns over
teratogenicity, compliance
Paromomycin Intramuscular administration;
registered in India; less effective in
Sudan
Clinical trials Amphotericin B lipid formulations Other formulations shown effective
in clinical studies
Co-administrations:
AmBisome þmiltefosine,
AmBisome þ paromomycin,
miltefosine þ paromomycin
Highly effective, short course
treatment in phase III trials in India;
in further clinical studies
CL
First-line drugs Pentavalent antimonials:
sodium stibogluconate
(Pentostam)
Standard treatments; variable
efficacy between types and species
of Leishmania
Meglumine antimoniate
(Glucantime)
Amphotericin B (Fungizone) For specific types in South America
Pentamidine For specific types in South America
Paromomycin (topical formulation) Marketed formulation
Clinical trials Paromomycin (topical formulation,
Phase III)
Well-tolerated formulation, also
containing 0.5% gentamicin
Miltefosine (oral, Phase III)
Imiquimod Topical immunomodulator, adjunct
therapy to antimonials in Phase II
HAT
Haemolymphatic
stage
First-line drugs Pentamidine Used for T. b. gambiense disease
Suramin Used for T. b. rhodesiense disease
Clinical trial Fexinidazole Phase II trials to start in 2012
SCYX-7158 Phase I trials in 2012
CNS stage
First-line drugs Melarsoprol Only drugs available for
T. b. rhodesiense disease
Eflornithine Used for T. b. gambiense disease
Nifurtimox/eflornithine
co-administration
Approved for use by WHO in 2009
Used for T. b. gambiense disease
Clinical trial Fexinidazole Phase II trials in 2012
SCYX-7158 Phase I trials in 2012
Chagas disease
Continued
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methods to improve interpretation of clinical trials. The emergence of
Product Development Partnerships including the Geneva-based Drugs
for Neglected Diseases initiative (DNDi) and the US-based Consortium
for Parasitic Drug Development and Institute for One World Health
(IoWH) provided formats to enable progression of compounds through
clinical trials thus filling a gap created by the abandonment of these
areas by the Pharmaceutical industry.
Management of Leishmaniasis
Leishmaniasis is endemic in 98 countries in Asia, Africa, South and
Central America and southern Europe. Leishmaniasis is often consid-
ered a disease complex with two major manifestations, VL and CL.
Additionally, there is a number of rarer forms, including mucocuta-
neous (MCL), diffuse (DCL) forms of CL and post-kala-azar dermal
leishmaniasis (PKDL).5 There is an estimated incidence of around 0.5
million cases of VL and 1.5 million of CL. The Leishmania parasite is
transmitted by female phlebotomine sandflies, in which the flagellated
promastigote form divides and develops into an infective metacyclic
form. Following the bite of the sandfly, the promastigote invades
various macrophage populations where it transforms to the amastigote
form that survives and multiplies in the phagolysosomal compartment
of this host cell. In VL, normally caused by Leishmania donovani
and Leishmania infantum (equivalent to Leishmania chagasi in
S. America), the infection progresses to a potentially fatal disease if un-
treated. Different pathologies are associated with these species, even L.
donovani having different pathologies in India and Sudan. This is
Table 1 Continued
Drug Comments
Acute stage
First-line drugs Nifurtimox Oral, long course, known toxicities
and T. cruzi strain sensitivity
variation
Benznidazole Oral, long course, known toxicities
and T. cruzi strain sensitivity
variation; paediatric formulation in
late development with DNDi
Indeterminate stage/
early chronic stage
No standard treatments
Clinical trials Benznidazole BENEFIT trial to report in 2012
Antifungal triazoles: posoconazole
and ravuconazole pro-drug
Entered clinical trials in 2011 with
Merck and Eisai/DNDi
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further complicated by the observations that some strains of L. infan-
tum can cause CL and that post-treatment some L. donovani-infected
patients develop into the DCL form, PKDL. Since 1985, cases of
HIV-VL co-infection have been reported with increasing numbers of
cases in East Africa (23% of all VL cases in NE Ethiopia).6 CL also
presents in patients in many different forms, though most patients have
limited cutaneous lesions that self-cure within 6–18 months leaving
scarred tissue. CL has social and economic impact and is a stigmatizing
disease as most lesions are on exposed regions of the skin, for example,
face, arms and legs. Over 15 species of Leishmania cause CL in
humans, with species such as Leishmania major, Leishmania tropica
and Leishmania aethiopica in the Old World and Leishmania mexi-
cana, Leishmania amazonensis, Leishmania braziliensis, Leishmania
panamensis and Leishmania guyanensis in the New World. Generally,
L. donovani and L. tropica are the sources of anthroponotic infections,
whereas L. infantum and the other CL-causing species are zoonotic
infections.7
Four characteristics of Leishmania biology are particularly germane
to drug efficacy, namely (i) the intracellular location of the amastigote
target form in the macrophage’s low pH phagolysosomal compartment;
(ii) the different pharmacokinetic requirements of drugs that distribute
to the liver, spleen, bone marrow in VL or the skin in CL; (iii) the sig-
nificant differences in drug sensitivities of the 17 species of Leishmania
that cause leishmaniasis in humans and (iv) the influence of the
immune suppression associated with leishmaniasis, which can render
some drugs less effective.
Clincial signs and diagnosis
The leishmaniases present in a variety of ways. CL manifests as an
open sore at the site of the insect bite and will frequently self-heal,
albeit leaving a scar. DCL is more problematic causing lepromatous
type lesions disseminated across the skin and can be more difficult to
heal. The MCL form, endemic in parts of latin America, starts with
skin sores but these spread to the mucosal membranes of the face and
profound inflammatory damage can lead to the erosion of nostrils and
mouth in particular. VL, after initial skin lesions, takes 2–8 months to
develop gross inflammatory reactions within the viscera (liver and
spleen in particular) and is usually fatal unless treated. Microscopic
identification of parasites has been central to diagnosis. The detection
of amastigotes in the samples from the lymph nodes, bone marrow,
liver, spleen or skin lesions is a first step. For VL, some techniques, like
spleen aspiration, can cause life-threatening complications and should
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be performed only by trained personnel. Bone marrow aspiration has a
lower sensitivity. PCR is more sensitive than microscopic examination
and has become the first-line test in referral hospitals and research
centres. Quantitative PCR allows an accurate diagnosis in venous
blood samples, thereby avoiding bone marrow aspiration.
Serological tests are the most widely used indirect method. Indirect
fluorescence antibody, enzyme-linked immunosorbent assay (ELISA) or
western blot require equipment that has not been optimized for field
settings. Both the direct agglutination (DAT) and immunochromato-
graphic tests (ICT) using the rK39 antigen (in a dipstick format), have
proved to have a high sensitivity and specificity and translate readily to
peripheral health centres. Serological tests have limitations as specific
antibodies remain detectable for several years after cure, hence there is
a need for a field-adapted antigen test. A latex agglutination test detect-
ing a heat-stable, carbohydrate antigen in the urine of VL patients
showed good specificity but low-to-moderate sensitivity and further
innovation is needed in this area.8
Current drugs: VL
Pentavalent antimonials
Pentavalent antimonials (Fig. 1), the standard drugs for 70 years, are
now almost obsolete in the key endemic area in Bihar, India due to
drug resistance. However, sodium stibogluconate (Pentostam),
Fig. 1 Drugs used in leishmaniasis therapy: (A) amphotericin B; (B) paromomycin; (C) milte-
fosine; (D) sodium stibogluconate.
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meglumine antimoniate (Glucantime) and a generic low-cost brand of
sodium stibogluconate remain useful in treatments in the rest of the
world. Here too, however, long courses (up to 30 days), parenteral
administration and the known toxicity profile, including hepatotoxic,
nephrotoxic and potentially fatal cardiotoxic effects, limit use.5,9 Their
chemical structure remains poorly defined. Much current research is
focused on the mechanisms of resistance to this class of drugs.10
Amphotericin B and lipid formulations
Amphotericin B (Fig. 1), normally considered a second-line drug, is
now first-line treatment in Bihar, India following the loss of effective-
ness of pentavalent antimonials. This drug is now at the forefront of
VL treatment in a number of lipid formulations, developed during the
1980s for the treatment of systemic mycoses in immunocompromised
patients. Of the several that have proved effective in the treatment of
VL, only the liposomal formulation, AmBisome, has become a stand-
ard treatment, registered for the treatment of VL in a number of coun-
tries.11 Recently, a single-course therapy of 10 mg/kg has been shown
to cure 95% of patients in India.12 A significant reduction in price
negotiated by the World Health Organization (WHO) with the produ-
cers (Gilead), currently $18 for a 50 mg ampoule) was followed in
2012 by a donation of 50 000 treatments. However, several ampoules
are required for a single-course treatment, and adverse events and tem-
perature stability (manufacturer guarantee 258C) remain issues. A re-
curring issue around all the VL treatments, discussed in this section,
are regional differences in response rates. Clinical studies have sug-
gested that AmBisome was most effective in the treatment of VL
patients in India, less so in East Africa and even less so against L. in-
fantum (L. chagasi) in South America.13 The worldwide use of
AmBisome for VL requires further study, especially in East Africa
(www.dndi.org).
Paromomycin (aminosidine, monomycin)
Over 50 years ago, the aminoglycoside paromomycin (Fig. 1) was
shown to possess anti-leishmanial activity. Following the studies that
showed a parenteral formulation could cure VL in the 1980s, paromo-
mycin moved slowly through clinical trials with WHO/TDR in the
1990s and the IoWH in the 2000s. Phase III clinical trials in India
demonstrated 94% efficacy (15 mg/kg for 21 days, i.m.) leading to
registration for treatment of VL in India in 2006.14 Despite the low
Management of trypanosomiasis and leishmaniasis
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cost (estimated $10.00 per course), the drug has not yet become part
of the treatment options for VL patients in the subcontinent, although
a phase IV trial in 2008–09 showed a cure rate of 94.2% at 6 months
post-treatment (P. Desjeux, IoWH, pers comm.). A phase III VL clinic-
al trial with the same dose in East Africa, conducted by DNDi, showed
lower efficacy, particularly in Sudan where the 15 mg/kg regime gave a
,50% cure rate, whilst a dose of 20 mg/kg for 21 days gave only an
85% cure rate, insufficient for consideration as a monotherapy.15 The
reason for this difference is not understood.
Miltefosine
The anti-leishmanial activity of the phospholipid derivative, miltefosine
(Fig. 1), identified in the 1980s led to the first oral treatment for VL.
Clinical trials supported by WHO/TDR and Zentaris (the then manu-
facturing company), showed 94% efficacy in adults and children and
miltefosine was registered for treatment of VL in India in 2002.16 It
was the first anti-leishmanial to undergo phase IV studies and has been
used in the VL Elimination Programme for the Indian sub-continent.
Issues around the use of miltefosine include (i) potential teratogenicity,
which requires women of child-bearing age to take contraception for
up to 3 months post-treatment due to long half-life of the drug, (ii) the
28 days oral treatment which can lead to poor compliance and relapses
and (iii) concerns about drug resistance (Fig. 1).
Other new treatments
Drug combinations shorten courses of therapy, reduce toxicities through
lower dosage and diminish the selection of resistant mutations. Drug
combinations are not yet available for VL, although co-administration
(either concomitant or sequential) of three available anti-leishmanial
drugs has been tested following experimental and pre-clinical toxicoki-
netic studies.17 Phase III trials on VL in India have shown that
co-administrations of AmBisome þ miltefosine (single dose iv þ oral 7
days, sequential), AmBisome þ paromomycin (single dose iv þ 10 days
i.m., sequential) and miltefosine þ paromomycin (10 days þ 10 days
i.m., concomitant) gave a 98% cure rate. This reduces treatment time (30
days compared with a potential 8 days) and should have an impact on
disease control. Antimonials were not included due to drug resistance in
India. In Sudan, a phase III trial on a co-administration of sodium stibo-
gluconate and paromomycin (17 days) has recently demonstrated equiva-
lent efficacy to the longer courses of monotherapies.
M. P. Barrett and S. L. Croft
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Other forms of VL
Some VL-treated patients develop the cutaneous manifestation, PKDL,
with parasite persistence within the context of an immunological re-
sponse. Differences in Indian and Sudanese PKDL include frequency, age
profile and rates of self-cure. Whether PKDL results from specific types
of drug treatment is unlikely. Treatment based upon long courses of an-
timonial drugs, and small studies with miltefosine and AmBisome have
reported improved cure rates. An immunotherapeutic approach, antim-
onial drug plus BCG, showed a higher cure rate than drug alone in Sudan.
HIV/Leishmaniasis co-infections
The standard drugs have been used in various regimens to treat VL in
co-infection cases. Relapse rates are variable but up to 85% and fre-
quently recorded.6 Co-infection increases the risk of VL developing in
an infected human by 100–2300-fold, with accompanying issues of
reduced response to therapy, and greatly increased probability of
relapse. Currently, there is no successful defined treatment regimen for
HIV-VL patients. Different policies have been adopted by countries
with some recommending treatment with anti-retrovirals followed by
treatment with anti-leishmanial drugs, whilst others have recommended
maintenance therapy. In Southern Europe, this maintenance therapy is
frequently based upon lipid amphotericin B formulations.
Current drugs: CL
In comparison to VL there are limited proven treatments for CL.
Concerns over the reliability of data in the absence of randomized
placebo controlled trials was reported in two Cochrane analyses of
trials on New World CL and Old World CL, concluding that most clin-
ical studies could not be analysed as they did not meet acceptable stan-
dards.18,19 A standardized protocol allowing clinical trials to present
comparative data, defines start points (recruitment of patients with
new or old lesions) and endpoints (resolution of lesion or complete
re-epithelialization) has been proposed.20
Pentavalent antimonials, amphotericin B and pentamidine
The three traditional standard drugs have been used widely in the treat-
ment of CL but today are only recommended for the treatment of spe-
cific forms. Pentavalent antimonials have proved inconsistent in their
effectiveness across the different Leishmania species whilst the use of
pentamidine and amphotericin B are limited to specific types of CL in
South America.
Management of trypanosomiasis and leishmaniasis
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Paromomycin (aminosidine, monomycin)
Paromomycin has been used in various formulations for CL over
several decades. Focus in the past three decades has been on topical
formulations with a 15% paromomycin ointment (with the penetrating
enhancement agent, 12% methylbenzethonium chloride), proving ef-
fective in clinical studies and currently available from TEVA (Israel).
The search for more effective and less irritant topical formulations con-
tinues and a formulation of 12% paromomycin (with 0.5% gentamicin
and 10 surfactants), which showed efficacy against L. major CL in a
phase II trial in Tunisia, is now in phase III studies.21
Miltefosine
Oral miltefosine also has some variable, species-dependent effectiveness
against CL. It is registered for the treatment of CL in Colombia and
has been shown effective against various forms of CL. Again variation
in species sensitivity has proved an issue in the New World and
improved diagnostics are required.
Other treatments
For L. major and L. tropica infections there is evidence that the antifun-
gal azoles, fluconazole and itraconazole have some effect. Recently, the
triazole, posoconazole, which showed potential in experimental studies,
was effective in a clinical study. One of the drugs identified in the
Cochrane analyses as contributing towards cure was the anti-
inflammatory drug pentoxyphylline, used as adjunct therapy to antimo-
nials.22 As CL treatment can also aim to accelerate self-cure through
immune mediated means, adjunct therapy with immunomodulators also
has potential. BCG has been used extensively in combination with anti-
monials in Venezuela, and the anti-viral TLR7 agonist, imiquimod, in
Peru.23 A trial on CL patients in Peru country showed 75% cure for imi-
quimod plus antimonials compared with 58% for antimonials alone.23
Management of HAT
HAT, often referred to as sleeping sickness in its second stage when
neurological manifestations associated with parasites in the brain
become apparent, is endemic to sub-Saharan Africa. Its prevalence had
grown to an estimated 300 000 cases by 1998 from a position of near
control in the 1960s.24,25 Enhanced surveillance, distribution of free
M. P. Barrett and S. L. Croft
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drugs and implementation of several clinical trials led to a steady
decline in incidence in the twenty-first century with reported case
numbers ,7000 and a hope of elimination by 2020.
Trypanosoma brucei gambiense is found in West and central Africa.
Trypanosoma brucei rhodesiense is found in East and southern Africa.
The parasites can be distinguished by genetic markers, e.g. the serum
resistance associated (sra) gene defines T. b. rhodesiense26 and protects
against a human trypanosome lytic factor (TLF), or apoliporotein L1
(ApoL1), that is responsible for immune-independent lysis of most
trypanosome species. Trypanosoma brucei gambiense does not have
the sra gene, avoiding TLF lysis by other means.26 Trypanosoma
evansi, generally infectious only to non-primate mammals has been
found to infect humans with rare genetic defects in ApoL1.26
The process of antigenic variation makes vaccination an unlikely
option in HAT control. Trypanosomes are transmitted by tsetse flies,
Glossina ssp., and the distribution of the disease is restricted to areas
where tsetse thrives. Tsetse clearance can be effective in control; the
Island of Zanzibar, for example, was declared trypanosome free fol-
lowing intense efforts at tsetse control. However, translation to a
continent-wide approach is difficult and chemotherapy remains at the
forefront of HAT management.27
Clinical signs and diagnosis
Patients exposed to infected tsetse fly bites will develop the disease. In
the first, hemolymphatic stage parasites proliferate in the blood and
lymphatic systems, and symptoms such as headache and general
malaise ensure. At Stage 2 the parasites have invaded the central
nervous system including the brain, and progressive neurological break-
down, including psychiatric disorders, depression and altered sleep–
wake patterns, ensues. T. b rhodesiense progresses to Stage 2 in weeks
to months, whereas it takes on average 18 months for gambeinse
disease to reach Stage 2.
Diagnosis in active screening campaigns involves a primary serologic-
al screen using the Card Agglutination Test for Trypanosomiasis
(CATT), which targets antibodies produced against the common
LiTat1.3 variant surface antigen which is expressed early in most
T. b. gambiense infections. However, variable sensitivity (and failure to
detect rhodesiense parasites which lack the CATT antigen) means
microscopical identification of parasites in the lymph or blood is
required for confirmation,28 whilst diagnosis at Stage 2 (necessary as
therapy is stage dependent) requires the identification of either para-
sites, or else white cells in CSF. Novel sensitive molecular diagnostics
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using PCR or an isothermal DNA amplification technique (the so-called
LAMP approach) along with several other tests for new biomarkers and
parasite-enrichment techniques might soon yield improved diagnostics.
Current drugs
Current drugs for HAT are unsatisfactory: with varying degrees of tox-
icity, a need for parenteral administration and efficacy ,100% with re-
sistance a growing problem. For stage 1 HAT, pentamidine is used for
T. b. gambiense and suramin for T. b. rhodesiense infection. For Stage
2, the arsenical melarsoprol remains the only option for rhodesiense
disease, although for the majority of cases (.95% of cases being
T. b. gambiense) eflornithine has become first-line treatment, particu-
larly in combination with nifurtimox, in the nifurtimox–eflornithine
combination therapy (NECT). The gratis donation to WHO of eflor-
nithine, melarsoprol and pentamidine by Sanofi-Aventis and suramin
and nifurtimox by Bayer has been critical in the successful campaign
against HAT in the twenty-first century.
Pentamidine
Pentamidine (Fig. 2) has been used to treat first-stage T. b. gambiense
disease since the 1940s.29 It is given at 4 mg kg21 once per day, usually
over a 7-day period intramuscularly (intravenous injection induces a
Fig. 2 Drugs used in human African trypanosomiasis therapy: (A) eflornithine; (B) melarso-
prol; (C) suramin and (D) pentamidine.
M. P. Barrett and S. L. Croft
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potentially dangerous hypoglycaemic response). Injection-site dolour,
nephrotoxicity, leucopenia and liver enzyme abnormalities are
common adverse events. The drug is potent, with in vitro trypanocidal
IC50 values in the order of 1–10 nM. Accumulation of drug to high
concentrations by several transporter systems appears to contribute to
selectivity, although loss of uptake can also contribute to resistance.29
The pharmacology of pentamidine presents various difficulties includ-
ing extensive tissue retention and binding to serum proteins giving a
large volume of distribution and long-terminal half-life, while little
drug can enter the brain. Trials of a shortened, 3 day, course of pent-
amidine are ongoing and will reduce dose and hospitalization time if
successful.
An orally available analogue of pentamidine, pafuramidine maleate
(DB289), is a methoxy prodrug that penetrates intestinal epithelia and
converts systemically to the diamidine furamidine (DB75) (Fig. 2).29 A
phase III trial showed the oral formulation to be of comparable efficacy
to injected pentamidine; however, an extended phase I safety trial
using 14 day dosing (instead of the successful 10 day dosing in the
phase III trial) demonstrated unacceptable nephrotoxicity and develop-
ment was halted.29
Suramin
Suramin was first used against HAT in 1922.30 In a typical course it is
given by slow intravenous injection once every 3–7 days, over a 4 week
period. Suramin is .99% protein bound in serum with a terminal half-
life of 41–78 days. Blood–brain barrier permeation is minimal
meaning it is useful only in Stage 1. The uptake into trypanosomes is
via ISG75 receptor-mediated endocytosis and interference with mul-
tiple points in the endocytic pathway leads to decreased suramin sensi-
tivity,31 although how it actually kills cells once inside remains
unknown. Adverse reactions include pyrexia, nephrotoxicity, nausea,
urticaria, neuropathy and anaemia, particularly when used at high
doses as a potential inhibitor of HIV infection.30
Melarsoprol
Melarsoprol (Fig. 2) emerged in the 1940s as a safer drug than previ-
ous arsenic derivatives. However, an often fatal reactive encephalop-
athy afflicts 5–10% patients taking the drug. Other adverse effects
include pyrexia, headache, pruritus, thrombocytopaenia and heart
failure. Melarsoprol is given by intravenous injection as a 3.6% solu-
tion in propylene glycol, usually now over a 10-day course32 which
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replaced earlier regimens where it was given, with interruptions, over a
month. Oral dosing of cyclodextrin–melarsoprol conjugates cured a
stage 2 infection in mice, with reduced host toxicity.33
Co-administration of corticosteroids (e.g. prednisolone) also provides
limited protection against the reactive encephalopathy.
Selective uptake via specific transporters plays a key role in the select-
ive toxicity of melarsoprol and loss of transport relates to resistance
(including cross-resistance to pentamidine if the appropriate set of
transporters is lost27). Treatment failures reached alarming levels in
many foci in the 1990s and 2000s. Trypanocidal metabolites of melar-
soprol only reach levels in brain at 1–2% of maximum plasma levels
which means that a relatively low drop in parasite sensitivity to drug
could cause treatment failure and recrudescence from the brain.
Eflornithine and Nifurtimox eflornithine combination therapy (NECT)
Eflornithine (D,L-a-difluoromethyl ornithine) inhibits the polyamine
biosynthetic enzyme ornithine decarboxylase, which turns over more
rapidly in man than trypanosomes, partly explaining the selective effect
of the drug. In monotherapy it is given at 100 mg kg21 body weight at
6 h intervals (i.e. 400 mg kg21 per day) by intravenous infusion for 14
days.34 This high frequency of administration relates to a short plasma
half-life (3 h) and poor potency (in vitro IC50 values of 81–693 mM),
although the action of the immune system also contributes to in vivo
activity.34 The CSF to plasma ratios are between 0.1 and 0.9 in
humans. Adverse effects include fever, headache, hypertension,
macular rash, peripheral neuropathy and tremor, gastrointestinal pro-
blems including diarrhoea. Infusion-associated septicaemia has been a
major issue.
An amino-acid transporter, TbAAT6, mediates the uptake of eflor-
nithine into trypanosomes and resistance relates to loss of the trans-
porter.35 The introduction of a combination of eflornithine with the
unregistered trypanocide nifurtimox36 aims to delay the emergence of
resistance and improve administration regimens. The combination
regimen uses intravenous eflornithine at 200 mg/kg every 12 h for 7
days (i.e. 14 rather than 56 infusions), with nifurtimox being given
orally three times a day for 10 days. The advantages in cost and con-
venience have rapidly made NECT the treatment of choice for stage 2
disease (the cost issue currently being mitigated by the gratis provision
of drugs to WHO).
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New drug candidates for HAT
Orally available drugs, preferably of reduced administration duration
for HAT, are highly desirable. A ‘pipeline’ of new compounds entering
clinical trials has now emerged (Fig. 3).37
Fexinidazole
Fexinidazole (Fig. 3) is a 2-substituted 5-nitroimidazole now being
taken forward by the Drugs for Neglected Diseases initiative (DNDi)
over the past 6 years. Although of modest potency (IC50 values around
1 mM), the compound is active in mouse models of stage 1 and stage 2
diseases,38 curing the stage 2 model at 100 mg/kg twice per day oral
dosing for 5 days (Fig. 3).
It is metabolized to sulphoxide and sulphone derivatives (with
similar potency to the parent compound) and has good CNS penetra-
tion. As most nitro-heterocycles, fexinidazole is positive in bacterial
Ames genotoxicity tests but not in mammalian assays. Other safety
tests also indicated no adverse events up to 200 mg/kg in rats and the
drug entered phase I clinical trials in 2010, with phase II trials planned
to start in 2012.
Fig. 3 Drugs in or approaching clinical trials for HAT therapy: (A) fexinidazole; (B)
SCYX-7158; (C) DB289 (pafuramidine); (D) DB75 (furamidine) and (E) CPD0801.
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SCYX-7158
The benzoxaborole class was developed against Trypanosoma brucei in
a collaborative venture between Anacor Pharmaceuticals, SCYNEXIS
and DNDi.39 A 6-carboxamido-based series was chosen for optimization
based on trypanocidal activity and pharmacokinetic properties, includ-
ing brain permeation. Ultimately, SCYX-7158 (Fig. 3) was selected for
further development. Its modest in vitro potency (IC50 around 1 mM)
was offset by good pharmacokinetic properties giving 100% cure in a
mouse model of stage 2 disease following a 25 mg/kg once a day for 7
days oral dosing.39 Toxic effects have been minimal in preclinical evalu-
ation and the compound entered phase I trials early in 2012.
Stage 2 active dicationic molecules
Several aza analogues of pafuramidine’s active diamidine product, fura-
midine (DB75) (Fig. 3), including CPD-0802 (or DB-829) (Fig. 3),
DB-868 and 28DAP010 cured mouse and primate models of stage 2
trypanosomiasis.29 CPD-0802 at 20 mg/kg once daily, intraperitone-
ally, for 10 days cured the GVR35 CNS mouse model while a daily
5 mg/kg intramuscular injection for 5 days cured a vervet monkey
model of stage 2 (T. b. rhodesiense) disease. The methoxy prodrug of
CPD0802 also cleared the GVR35 mouse model when given orally.
Renal toxicity is an issue that requires consideration in the develop-
ment of diamidines; CPD-0802 accumulates in the rat kidney at con-
centrations around 10 times lower than furamidine. This potentially
improved safety profile and the higher risk–benefit margin required for
stage 2 drugs places these compounds in the pre-clinical part of the
pipeline for HAT drug development.
Management of American trypanosomiasis
American trypanosomiasis or Chagas’ disease, caused by Trypanosoma
cruzi, afflicts 8–10 million people, mainly in Central and South
America. Prevalence in non-endemic countries is increasing as emigra-
tion from endemic countries brings hundreds of thousands of cases to
the USA, Europe and elsewhere.40 Natural transmission depends on
reduviid bugs of the genus Triatoma that convey parasites in their
faeces whilst taking blood meals from their mammalian hosts. Blood
transfusion is also a key route of transmission. Trypanosoma cruzi
infects several mammalian species in addition to humans. Molecular
analysis has revealed that at least six distinct lineages can be classified,
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with genetic distances between these classified types being as far as
those that divide Leishmania into distinct species. A definitive link
between different epidemiology and different clinical symptoms has yet
to be made.
Following entry into the host, parasites invade host cells and differen-
tiate into replicative amastigote forms (in the cytosol rather than pha-
golysosome as seen in Leishmania). The acute stage of infection
involves inflammatory reactions to the parasites and general symptoms
such as fever and malaise. After this patients enter an indeterminant
phase: characterized by a lack of symptoms and failure to find parasites
in biopsy, or even detect their presence by sensitive DNA based techni-
ques. This phase can last 5–15 years (or more), many individuals
dying of causes not related to the trypanosome infection. Others will
go on to develop a symptomatic chronic disease where pathologies
ranging from cardiomyopathy to megaoesophagous or megacolon lead
to death. Persistence of parasites eventually leads to the inflammatory
responses that underlie these chronic Chagasic pathologies.40
Coordinated programmes to destroy the triatomine vectors have been
effective in reducing Chagas’ incidence,40 although the longevity of in-
fection makes it probable that human or other wild animal reservoirs
will maintain an infectious cycle beyond the dates when sustained insect
control becomes non-viable. Although hope exists that immunization
could be used in Chagas control, useful vaccines are not available yet.
Clinical signs and diagnosis
Infection follows the entry of parasites from insect faeces in lesions fol-
lowing the feed of the reduviid bugs. Facial swelling, especially around
the eye (Romana’s sign), is common and general malaise accompanies
the acute phase following infection. A long, asymptomatic, indetermin-
ate phase can follow where parasites are difficult to find. This can last
in excess of 10 years. In some cases inflammatory responses to residual
parasites induce progressive and sometimes fatal inflammatory damage
to the heart, oesophagus, colon or other organs.40
In addition to symptomatic diagnosis and microscopy in the acute
stage when trypomastigotes can be found in the blood, serological
diagnosis using T. cruzi antigen to detect antibody responses is routine-
ly performed.40 PCR techniques have also been evaluated and particu-
larly in the indeterminate and chronic phases, and have been adopted
for use in clinical trials and surveillance studies. Traditionally, xeno-
diagnosis, involving feeding laboratory reared triatomid nymphs on
blood of patients, was used along with haemoculture as classical para-
sitological methods.
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Current drugs
Only two drugs, both nitroheterocycles, are recommended for treat-
ment of Chagas disease.41 Nifurtimox is a nitrofuran from Bayer,
whilst benznidazole, produced for many years by Roche, is a 2-
nitroimidazole. The latter’s supply has been a cause of ongoing
concern since Roche stopped the production with transfer of manufac-
ture to the Brazilian government associated pharmaceutical company,
LAFEPE laboratories.
Nifurtimox
Nifurtimox (Fig. 4) was introduced in the 1960s to treat acute Chagas
disease.41 The drug is trypanocidal, against both circulating trypomas-
tigotes and amastigotes. Its use for Chagas declined for several years
but the enhanced manufacture to contribute to NECT use for HAT,
and recent interruptions in availability of benznidazole, have led to
increased use. Clearance of nifurtimox from blood is fast (plasma elim-
ination half-life of around 3 h) and trypanocidal potency is weak and
so the drug is given for prolonged periods (in tablet form, adults receiv-
ing 8–10 mg/day for 90 days while juveniles receive 15 mg/day).
Nifurtimox appears to act primarily through the metabolism to a react-
ive trinitrile species and different T. cruzi lineages show significant dif-
ferences in susceptibility possibly because of varying expression levels
of nitroreductase enzymes required for activation. Toxic effects to the
central and peripheral nervous systems and gastrointestinal problems
(nausea, stomach cramps, vomiting and diarrhoea) are common.
Benznidazole
Benznidazole (Fig. 4), introduced in the 1970s, has variable activity
across different T. cruzi strains, relating to variable reductive activation
by metabolism. It is given orally (5–7 mg/day for 60 days in adults and
5–10 mg/day in juveniles).41 A new formulation to facilitate paediatric
administration is currently under development through DNDi. Side
Fig. 4 Drugs used in Chagas disease therapy: (A) benznidazole and (B) nifurtimox.
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effects are also common, principally hypersensitivy reactions manifest-
ing themselves in dermal lesions, but intestinal and neurological side
effects are reported too. Clear-cut evidence of enhanced risk of cancer
is not reported for either drug, but in the absence of long-term follow-
up studies this might be missed. An important trial (benznidazole
evaluation for interrupting trypanosomiasis, BENEFIT trial) evaluating
the use of the drug in chronic stage Chagas is under way with results
due late in 2012.42
Treatment of the symptomatic complications of Chagas disease is
also useful, thus for Chagasic heart disease, salt restriction, diuretics,
digitalis, angiotensin converting enzyme inhibitors, beta blockers, anti-
coagulant treatment for atrial fibrillation, pacemakers or automatic
cardiodefibrillator implantation are all used when necessary. Surgery
too can be used including heart transplantation for patients with
advanced chagasic cardiomyopathy, or surgical removal of afflicted
areas of oesophagus and colon in the other megasyndromes.
Drugs under development for Chagas disease
Development of new drugs for Chagas disease is fraught with diffi-
culty, not least because patients entering the indeterminate stage are
asymptomatic and the difficulty to detect parasites then and in early
chronic infections complicates any definitive assessment of cure.
Notwithstanding, several compounds are in clinical trials for Chagas
disease. Two antifungal lanosterol-14 alpha-demethylase inhibitors,
posoconazole (Fig. 5) (developed by Schering Plough, now with
Merck).43 and E1224 (a water-soluble prodrug of ravuconazole—devel-
oped by Eisai Pharmaceuticals with DNDi) are showing particular
promise. Both are orally available and in early stages of trials given
(400 mg twice per day for 60 days alone or with benznidazole for
posoconazole). A cysteine protease (cruzipain) inhibitor, K777—a
vinylsulfone (Fig. 5), has also shown efficacy in chronic rodent models
and is in preclinical development.44
Conclusion
The diseases caused by protozoa of the Order Kinetoplastida, collect-
ively known as the trypanosomiases and leishmaniases, afflict millions
of the world’s poorest people. Current treatments still rely upon toxic
arsenicals and antimonials and genotoxic nitroheterocycles. However,
in the past decade we have witnessed a surge in interest and commit-
ment to develop new drugs for these diseases and several new therapies
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have become available while other compounds are in clinical trials.45
Yet, given the known high attrition rates in drug development sustained
efforts to bolster and diversify the pipelines are still required if the
efforts to eliminate HAT in Africa and VL in India, as well as bringing
Chagas and other forms of leishmaniasis under control by 2020 are to
be successful.
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